plasmids: iPSC generation is markedly enhanced by p53 suppression 9 , and L-Myc is more potent and specific than c-Myc during human iPSC generation 10 .
We prepared four vector combinations ( Fig. 1a and Supplementary Table 2 ). The Y1 combination had six factors (OCT3/4, SOX2, KLF4, c-MYC, LIN28 and NANOG) in three episomal plasmids. The Y2 combination contained an additional TP53 (also known as p53) shRNA in one of the three plasmids. We replaced c-MYC and NANOG with MYCL1 (also known as L-MYC) in the Y1 and Y2 combinations, respectively, to yield the Y3 and Y4 combinations (Fig. 1b) .
We electroporated these seven combinations of episomal vectors (Y1-Y4 or T1-T3) into three human dermal fibroblast (HDF) lines and two dental pulp cell lines on day 0 (Fig. 1c) . We trypsinized transfected cells on day 7 and reseeded them onto feeder layers. We maintained the cells in embryonic stem cell (ESC) medium, and small cell colonies became visible ~2 weeks after transfection. We counted the number of colonies with a flat human ESC-like morphology and non-ESC-like colonies around day 30 (Supplementary Fig. 1 ). The Y4 combination resulted in significantly (P < 0.05) more iPSC colonies than did any of T1-T3 combinations (Fig. 1d) . In addition to these five parental cell lines, we obtained iPSC colonies from seven additional HDF lines with the Y4 combination of factors (Supplementary Table 3) .
We expanded ESC-like colonies derived with the Y4 combination for additional experiments. The majority of the colonies were expandable and exhibited a cellular morphology similar to that of human ESCs, characterized by large nuclei and scant cytoplasm (Fig. 2a,b) . We termed these episomal plasmid vector-derived iPSCs 'pla-iPSCs' . Ten of eleven clones we analyzed were karyotypically normal ( Supplementary Fig. 2 and Supplementary Table 4) . Short tandem repeat analyses confirmed that pla-iPSC clones were derived from HDFs and dental pulp cells (Supplementary Table 5 ). Reverse transcription-PCR (RT-PCR) analyses revealed that pla-iPSC clones expressed pluripotent stem cell markers, such as OCT3/4, SOX2, NANOG and DPPA5, at levels comparable to those in ESCs and retrovirus-derived iPSC clones ( Fig. 2c and Supplementary Figs. 3a, 4 and 5) . Global gene expression profiles also showed that pla-iPSC clones were similar to ESC and retroiPSC clones ( Supplementary Fig. 6 and Supplementary Table 6 ). The DNA methylation levels of CpG sites in the promoter region of NANOG were high in parental HDFs and dental pulp cells but were low in pla-iPSCs and ESCs (Fig. 2d) .
To examine whether episomal vectors persisted in pla-iPSCs, first we transfected an episomal vector encoding enhanced GFP We report a simple method, using p53 suppression and nontransforming L-myc, to generate human induced pluripotent stem cells (iPscs) with episomal plasmid vectors. We generated human iPscs from multiple donors, including two putative human leukocyte antigen (hLa)-homozygous donors who match ~20% of the Japanese population at major hLa loci; most iPscs are integrated transgene-free. this method may provide iPscs suitable for autologous and allologous stem-cell therapy in the future.
Genomic integration of transgenes increases the risk of tumor formation and mortality in chimeric and progeny mice derived from induced pluripotent stem cells (iPSCs) 1 . Integrationfree human iPSCs have been generated using several methods, including adenovirus 2 , Sendai virus 3 , the piggyBac system 4 , minicircle vector 5 , episomal vectors 6 , direct protein delivery 7 and synthesized mRNA 8 (Supplementary Table 1 ). However, reprogramming efficiency using integration-free methods is impractically low in most cases. Direct delivery of proteins or RNA is labor-intensive, requiring repeated delivery of the reprogramming factors. Modifying Sendai virus vectors or preparing synthesized RNA are technically demanding.
In the original report describing episomal plasmid vectors for reprogramming, the authors used seven factors, including POU5F1 (also known as OCT3/4), SOX2, KLF4, MYC (also known as c-MYC), NANOG, LIN28A (also known as LIN28) and SV40 large T antigen (SV40LT), in three different vector combinations 6 (T1-T3 combinations; Fig. 1a and Supplementary Table 2 ). In this study, we used two findings from our laboratory to enhance efficiency of reprogramming by episomal (EGFP) into fibroblasts and monitored fluorescence. Sixtyeight percent of the cells were fluorescent 1 week after transfection (Supplementary Fig. 7) . However, the signal quickly decreased thereafter, and only 2.4% of cells were fluorescent 4 weeks after electroporation. Then we estimated the copy numbers of the episomal vectors in established pla-iPSC clones. We designed a PCR primer pair for EBNA-1 sequence derived from Epstein-Barr virus to calculate the copy numbers of the episomal vectors and another primer pair for the endogenous FBXO15 locus to estimate the cell number. We detected ~200 copies of the episomal vectors per cell 6 d after transfection ( Fig. 2e and Supplementary Fig. 3b ). In contrast, we detected no EBNA-1 DNA in five of seven clones tested at passages 11-20 (~80-120 d after transfection). The remaining two clones contained ~0.001 and 2 copies, respectively. The latter clone likely had integrated the plasmid into a chromosome. experiments using five cell lines. ****P < 0.05 against T1, T2, T3 and control; ***P < 0.05 against T1, T3 and control; **P < 0.05 against T1 and control; *P < 0.05 against control. These data demonstrated that the episomal vectors were spontaneously lost in the majority of pla-iPSC clones.
We examined the differentiation potential of pla-iPSCs in vivo. Injection of pla-iPSCs into the testes of immunodeficient mice yielded tumors within 3 months. Histological examination confirmed that these tumors were teratomas and contained tissues of all three germ layers, including neural epithelium, cartilage and gut-like epithelium (Supplementary Fig. 8) .
We carried out directed differentiation of the pla-iPSCs into dopaminergic neurons in vitro (Online Methods). RT-PCR detected upregulation of SOX1, a marker of immature neural cells, and downregulation of OCT3/4 12 d after induction (Supplementary Fig. 9a ).
Immunostaining showed that the majority of cells expressed Nestin after 29 d, with some cells still proliferating and expressed Ki67 (Supplementary Fig. 9b-e) . Clusters of Nestin-expressing cells expressed PAX6, and more mature cell clusters expressed tyrosine hydroxylase, a marker of dopaminergic neurons ( Supplementary  Fig. 9f,g ). Tyrosine hydroxylase-expressing cells localized with the neural markers Tuj1 and MAP2ab, and the vesicular monoamine transporter VMAT2 (Fig. 2f-h and Supplementary  Fig. 9h-l) . Therefore, pla-iPSCs have the potential to differentiate into dopaminergic neurons.
We also examined whether pla-iPSC clones differentiated into retinal pigment epithelial cells using a modified stromal cellderived inducing activity method (Online Methods). Five of six pla-iPSC clones developed pigmented cell clusters after 30 d in conditioning medium of mouse PA6 stromal cells. The clusters grew and exhibited a squamous and hexagonal morphology, characteristic of retinal pigment epithelial cells (Fig. 2i,j) .
We examined the human leukocyte antigen (HLA) types of our dental pulp-derived iPSC lines. In a previous study only one HLA type had been detected in two dental pulp lines by a PCRreverse sequence-specific oligonucleotide probe (rSSOP) protocol 11 Table 7 ).
Others previously estimated that iPSC lines with 50 unique HLA homozygous haplotypes would match ~90% of the Japanese population at the HLA-A, HLA-B and HLA-DRB1 loci with twodigit specification 12 . We performed a similar estimation with fourdigit specification using the HLA Laboratory database and found that 50 unique HLA-homozygous donors would cover ~73% of the Japanese population ( Fig. 3a and Supplementary Table 8) . Approximately 75 and 140 unique donors would be needed to cover ~80% and 90%, respectively. It would be necessary to type ~37,000, ~64,000 and ~160,000 individuals, respectively, to identify these 50, 75 and 140 donors (Fig. 3b) .
Allografts using HLA-homozygous iPSCs may provide a therapeutic alternative to autologous grafts, for cases in which transplant is likely to be needed soon after injury; furthermore, they allow for the advance selection of safe clones 13 . The beneficial effects of matching at major HLA loci are well documented in renal transplantation 14, 15 , although recipients of allografts derived from HLA-homozygous iPSCs would still need immunosuppressants after transplantation because of other HLA antigens, non-HLA antigens and immunity by natural killer cells.
We report a simple, non-integrative method for reprogramming human cells. The increased efficiency and the use of nontransforming Myc should be useful to generate iPSCs from many donors, such as individuals with disease. The approach may also prove beneficial for generating human iPSCs for use in autologous and allologous stem cell therapy. methods Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemethods/. Accession codes. Addgene: 27076 (pCXLE-hOCT3/4), 27077 (pCXLE-hOCT3/4-shp53-F), 27078 (pCXLE-hSK), 27079 (pCXLE-hMLN), 27080 (pCXLE-hUL), 27081 (pCXLE-Fbx15-cont2) and 27082 (pCXLE-EGFP).
Note: Supplementary information is available on the Nature Methods website. onLine methods Cell culture. Human fibroblasts HDF1419, HDF1388, HDF1429, HDF1377, HDF1437 and HDF1554 were purchased from Cell Applications, and TIG121, TIG120, TIG114 and TIG107 were obtained from the Japanese Collection of Research Bioresources. Human fibroblasts were cultured in DMEM (Nacalai Tesque) supplemented with 10% FCS (Invitrogen). Human dental pulp (DP) cells were established from human third molars as described previously 11 and were maintained in mesenchymal stem cell growth medium (MSCGM; Lonza). Human ESC lines (KhES-1 and KhES-3) were obtained from Kyoto University. H1 and H9 were from WiCell Research Institute. Mouse embryonic fibroblasts (MEFs) were isolated from embryonic day 13.5 embryos of C57BL/6 mice. All mice used in this study were bred and killed appropriately following code of ethics of animal research committee in Kyoto University. MEF and mouse embryonic fibroblast cell line (SNL) cells 16 were cultured in DMEM supplemented with 7% (v/v) FCS, 2 mM L-glutamine and 50 units and 50 mg ml −1 penicillin and streptomycin, respectively. Established iPSCs and ESCs were maintained on mitomycin C-treated SNL cells in primate ESC medium (ReproCELL) containing 4 ng ml −1 of bFGF (Wako) as described previously 17 .
Vector construction. Efficient transgene expression was achieved by inserting the woodchuck hepatitis post-transcriptional regulatory element (WPRE) upstream of the polyadenylation signal of pCX-EGFP 18 . The episomal cassette was transferred from pCEP4 (Invitrogen). The EBNA-1 sequence (EcoRI and MfeI sites) was flanked by two loxP sequences, and the loxP-EBNA-1-loxP-OriP cassette was then digested with BamHI and BglII and inserted into the BamHI site of pCX-EGFP containing the WPRE. This episomal vector was designated pCXLE-EGFP.
Human cDNAs encoding OCT3/4, SOX2, KLF4, c-MYC, L-MYC, NANOG and LIN28 were amplified by PCR and cloned into pCR2.1 (Invitrogen). The translation termination codons of SOX2, c-MYC, L-MYC or LIN28 were replaced with a BamHI site and then were also cloned into pCR2.1. The cDNAs without a translation termination codon were thereafter ligated with 2A self-cleavage sequences in pBS-2A 19 with appropriate restriction enzymes to generate pBS-cDNA-2A. c-MYC-2A was digested with NotI and BspHI and was ligated into the NotI and NcoI sites of pBS-LIN28-2A in the same reading frame to generate the c-MYC-LIN28-NANOG cassette. These cDNA-2A or c-MYC-2A-LIN28-2A constructs were then ligated to another cDNA or NANOG in pCR2.1 with the translation termination codon in the same reading frame using appropriate restriction enzymes. These cDNA-2A-cDNA-stop or c-MYC-2A-LIN28-2A-NANOG-stop constructs were then inserted into the EcoRI site of pCXLE-EGFP. pCXLE-hOCT3/4-shp53 was constructed by inserting an shRNA expression cassette for p53, driven by the mouse U6 promoter, into the BamHI site of pCXLE-hOCT3/4. The pCXLE-Fbx15-cont2 was generated by inserting the FBXO15 cDNA into pCXLE-EGFP. Episomal vectors described previously 6 were obtained from Addgene (20922-20927).
Generation of iPSCs with episomal vectors. HDF and DP cells were cultured in DMEM supplemented with 10% FBS and mesenchymal stem cell growth medium (MSCGM), respectively. Three micrograms of expression plasmid mixtures were electroporated into 6 × 10 5 HDF or DP cells with Microporator (Invitrogen) with a 100-µl kit according to the manufacturer's instructions. The plasmid mixtures used in the experiments are shown in Supplementary Table 2. Conditions used were 1,650 V, 10 ms, 3 time pulses for HDF, and 1,800 V, 20 ms, 1 time pulse for DP cells. The cells were trypsinized 7 d after transduction, and 1 × 10 5 cells were re-plated onto 100-mm dishes covered with an SNL or MEF feeder layer. The culture medium was replaced the next day with primate ESC medium containing bFGF. The colonies were counted 26-32 d after plating, and those colonies similar to human ESCs were selected for further cultivation and evaluation. The pla-iPSC clones used in this study are summarized in Supplementary Table 9 .
(One lambda) at Repro Cell 23 . Additional HLA typing was performed with PCR-rSSOP using WAKFlow (Wakunaga Pharmaceutical) at HLA Laboratory. We performed pedigree study of 4,743 Japanese families (17,325 members) and identified 2,117 haplotypes, including interlocus recombinant haplotypes, which were detected in family studies. The haplotype frequency was calculated by direct counting on the parents in the families. Sequence-based typing was performed with AlleleSEQR (Atria Genetics) at Mitsubishi Chemical Medience Corporation.
To estimate coverage of Japanese population by HLA homozygous donors, we first calculated the frequencies of all possible combinations of the 2,117 HLA haplotypes shown in Supplementary Table 8 . Haplotype combinations that can be covered by a given homozygous donor were then identified and their frequencies were added to estimate coverage by the homozygous donor. When one HLA-A, HLA-B, HLA-DRB1 heterozygous individual was covered by multiple homozygous donors, we counted only once to avoid overestimation.
The expected number (EN) of each homozygous haplotype at a given population size (PS) was first calculated as; EN = (haplotype frequency) 2 
